Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Iterum Therapeutics PLC
NASDAQ ITRM
Data sourced from
and
and
Iterum Therapeutics PLC Pre-Tax Margin for the quarter ending March 31, 2024
Iterum Therapeutics PLC Pre-Tax Margin is NA for the quarter ending March 31, 2024. Pre-tax margin represents the proportion of a company's earnings before taxes (EBT) to its revenue. It is calculated by dividing the EBT by the revenue. This ratio indicates the profitability of the company's operations before the impact of taxes. A higher pre-tax margin suggests that the company generates a larger proportion of revenue as pre-tax profit, indicating stronger operational performance and efficiency.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: ITRM
| CEO | Mr. Corey N. Fishman |
| IPO Date | May 25, 2018 |
| Location | Ireland |
| Headquarters | Fitzwilliam Court, Dublin, Ireland, 2 |
| Employees | 14 |
| Sector | Healthcare |
| Industry | Biotechnology |
Description
Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and intravenous formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.
Key trends
Similar companies
Hoth Therapeutics Inc
NA
NA
StockViz Staff
September 16, 2024
Any question? Send us an email